Camptothecin derivatives and uses thereof

• US 8,168,648 B2
• Filed: 03/05/2010
• Issued: 05/01/2012
• Est. Priority Date: 03/06/2009
• Status: Active Grant

• Current Assignee: Taiwan Liposome Co., Ltd. (Woods Investment Co. Ltd.), TLC Biopharmaceuticals, Inc. (Woods Investment Co. Ltd.)
• Original Assignee: Taiwan Liposome Co., Ltd. (Woods Investment Co. Ltd.), TLC Biopharmaceuticals, Inc. (Woods Investment Co. Ltd.)
• Inventors: Kuo, Min-Wen, Chan, Yung-Hsu, Tseng, Yun-Long, Liew, Siong-Tern, Hong, Keelung
• Primary Examiner(s): Aulakh, Charanjit
• Application Number:
  US12/718,764
• Publication Number:
  US 20100227877A1
• Time in Patent Office: 788 Days
• Field of Search: 514/283, 546/48
• US Class Current: 514/283
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07D 491/22 in which the condensed system contains four or more hetero rings

Abstract

The present invention provides two new camptothecin derivatives, which were identified as S,R- and S,S-topotecan lactates, respectively. Both compounds have anticancer activities. Pharmaceutical compositions of the new camptothecin derivatives, and cancer therapies with the new camptothecin derivatives or their pharmaceutical compositions were also provided.

Claims

1. A compound which is represented by Formula I

2. The compound of claim 1, which is represented by Formula II

3. The compound of claim 1, which is represented by Formula III

4. A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier.

5. A pharmaceutical composition comprising a compound according to claim 2 or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier.

6. A pharmaceutical composition comprising a compound according to claim 3 or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier.